Among 4,153 propensity-matched adults with resistant hypertension and overweight/obesity, initiating GLP-1 receptor agonists (semaglutide or tirzepatide) as fourth-line therapy produced dramatically better outcomes than mineralocorticoid receptor antagonists (spironolactone or eplerenone) over median 1.4-year follow-up: MACE HR 0.63, all-cause mortality HR 0.34, major adverse kidney events HR 0.64, and acute kidney injury HR 0.62 — despite nearly identical systolic blood pressure reductions (~6 mmHg in both arms).
The mortality signal alone — a 66% relative risk reduction — is striking and demands scrutiny before clinical translation. This is a retrospective real-world cohort; residual confounding is the central concern. GLP-1RA initiators in 2017–2025 skew toward better-resourced, more engaged patients, and the TriNetX network captures billing codes rather than adjudicated events. The propensity score matching balanced observable covariates, but unmeasured factors like adherence, dietitian access, and baseline metabolic trajectory remain uncontrolled.
That said, the findings align mechanistically with what we know: GLP-1 receptors are expressed in cardiac and renal tissue, and semaglutide's FLOW and SELECT trials already established organ protection beyond glycemic or pressure effects. The novelty here is framing GLP-1RAs as a viable fourth-line antihypertensive alternative — a paradigm shift from a purely pressure-centric model toward cardiometabolic risk architecture. For clinicians managing obese patients whose hypertension resists three-drug regimens, this large dataset provides the strongest real-world signal yet that GLP-1RAs deserve prospective trial evaluation in this exact niche.